Established by the U.S. Constitution in 1789, the patent system grants inventors a temporary monopoly in exchange for publicly disclosing their inventions. Once a patent expires, others are free to replicate the innovation. This system balances private incentives with public benefits, rewarding inventors while promoting the spread of knowledge and long-term competition. 

Pharmaceutical patents for name-brand drugs typically last 20 years. High U.S. prescription drug prices provide strong incentives for innovation, a widely recognized success of the patent system. But higher prices also drive up healthcare costs, and Americans pay more for name-brand prescriptions than people in other countries. In response, President Trump signed an executive order aimed at lowering drug prices. 

However, 92% of prescriptions in the U.S. are filled with generics, which account for less than 13% of total drug spending. The authors of “The Economics of Generic Drug Shortages” note that while generic drugs have dramatically reduced healthcare costs, many have been in short supply in the past decade, including antibiotics such as amoxicillin and chemotherapy agents. 

Economically, a shortage occurs when demand exceeds supply at current prices. Typically, higher prices resolve shortages. However, in the generic drug market, price competition can actually exacerbate shortages. Hospitals, insurers, and wholesalers often lock in low prices through long-term contracts. To stay competitive, manufacturers cut costs by concentrating production in one or two facilities, often overseas in India and China, and avoid investing in spare capacity. 

The lack of spare capacity, combined with just-in-time inventory systems, limits flexibility and the ability to increase production rapidly. When demand increases, such as during disease outbreaks or the introduction of new uses (like GLP-1 inhibitors for weight loss), manufacturers struggle to increase production quickly. Cost-cutting can also compromise quality control, resulting in recalls and additional shortages. Natural disasters that cause plant shutdowns and geopolitical tensions that disrupt imports from India and China further exacerbate the risk of shortages. 

How can shortages be reduced? Pay more for quality, such as sourcing from vetted manufacturers. Speeding up FDA approvals for new producers and improving oversight of manufacturing quality may decrease supply disruptions. Reducing dependence on countries with geopolitical risks is also an option.  

Drug shortages disproportionately affect chemotherapy, antimicrobials, ADHD medications, and IV fluids. Shortages create real consequences for patient care and public health. Paying for high-quality additional production is a form of insurance, much like paying firefighters to be available in case of a fire.